The NSABP Study of Tamoxifen and Raloxifene (STAR) trial.
The NSABP Study of Tamoxifen and Raloxifene (STAR) trial.
复制标题
DOI：
10.1586/14737140.9.1.51
复制
发表时间：
2009-01
影响因子：
3.3
通讯作者：
Vogel VG
中科院分区：
文献类型：
--
作者：
Vogel VG
在他莫昔芬和雷洛昔芬的研究（STAR）试验中，乳腺癌风险增加的绝经后妇女在5年内接受口服他莫昔芬（20mg /天）或雷洛昔芬（60mg /天）。在服用他莫昔芬和雷洛昔芬的妇女中，有相同数量的浸润性乳腺癌病例。他莫昔芬组的非侵袭性乳腺癌病例少于雷洛昔芬组（风险比[RR]: 1.40； 95%可信区间[CI]: 0.98-2.02）。他莫昔芬组子宫癌发生率高于雷洛昔芬组（RR: 0.62; 95% CI: 0.35 ~ 1.08）。雷洛昔芬组血栓栓塞事件发生率较低（RR: 0.70; 95% CI: 0.54-0.91），服用雷洛昔芬的女性白内障和白内障手术发生率较低（RR: 0.79; 95% CI: 0.68-0.92）。STAR试验表明，雷洛昔芬在降低浸润性乳腺癌风险方面与他莫昔芬一样有效，不良事件风险较低，但非浸润性乳腺癌风险较高，无统计学意义。两种药物的其他癌症、骨折、缺血性心脏病和中风的风险相似。
In the Study of Tamoxifen and Raloxifene (STAR) trial, postmenopausal women at increased risk of breast cancer received either oral tamoxifen (20 mg/day) or raloxifene (60 mg/day) over 5 years. There were an equal number of cases of invasive breast cancer in women assigned to tamoxifen and raloxifene. There were fewer cases of noninvasive breast cancer in the tamoxifen group than in the raloxifene group (risk ratio [RR]: 1.40; 95% confidence interval [CI]: 0.98–2.02). There were more cases of uterine cancer with tamoxifen than with raloxifene (RR: 0.62; 95% CI: 0.35–1.08). Thromboembolic events occurred less often in the raloxifene group (RR: 0.70; 95% CI: 0.54–0.91) and there were fewer cataracts and cataract surgeries in the women taking raloxifene (RR: 0.79; 95% CI: 0.68–0.92). The STAR trial has shown that raloxifene is as effective as tamoxifen in reducing the risk of invasive breast cancer and has a lower risk of adverse events but a nonstatistically significant higher risk of noninvasive breast cancer. The risk of other cancers, fractures, ischemic heart disease and stroke is similar for both drugs.
登录
查看更多内容
影响因子：
--
作者：
Armstrong, Katrina;Quistberg, D. Alex;Guerra, Carmen
通讯作者：
Guerra, Carmen
DOI：
10.1016/s1521-690x(03)00070-8
发表时间：
2004-03-01
影响因子：
7.4
作者：
Goss, PE;Strasser-Weippl, K
通讯作者：
Strasser-Weippl, K
影响因子：
120.7
作者：
Cummings, SR;Eckert, S;Jordan, VC
通讯作者：
Jordan, VC
影响因子：
158.5
作者：
Barrett-Connor, Elizabeth;Mosca, Lori;Wenger, Nanette K.
通讯作者：
Wenger, Nanette K.
DOI：
10.1093/jnci/91.21.1829
发表时间：
1999-11-03
期刊：
JOURNAL OF THE NATIONAL CANCER INSTITUTE
影响因子：
--
作者：
Gail, MH;Costantino, JP;Vogel, V
通讯作者：
Vogel, V